Stock RCEL AVITA MEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings AVITA Medical, Inc.

Equities

RCEL

US05380C1027

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-20 EDT 		5-day change 1st Jan Change
8.3 USD +3.49% Intraday chart for AVITA Medical, Inc. -4.27% -39.50%
06-06 Avita Medical’s Cell Harvesting Device Treats First US Patient; Shares Rise 5% MT
05-31 Avita Medical's Recell Go Obtains Approval from US FDA MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company appears highly valued given the size of its balance sheet.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
AVITA MEDICAL, INC. Stock AVITA Medical, Inc.
-39.50% 215M
C
MODERNA, INC. Stock Moderna, Inc.
+35.14% 51.51B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.43% 39.03B
B
LONZA GROUP AG Stock Lonza Group AG
+35.88% 38.91B
A
CELLTRION, INC. Stock Celltrion, Inc.
-10.62% 26.68B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.63% 26.13B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-17.77% 19.91B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+40.52% 13.71B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.70% 12.38B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.41% 11.74B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
  1. Stock Market
  2. Equities
  3. RCEL Stock
  4. Ratings AVITA Medical, Inc.